Broadridge Q1 FY2027: Recurring Revenue Up 11%, But Margin Compression Yields Mixed Read

What happened

Broadridge's fiscal Q1 FY2027 showed a revenue/margin split: recurring revenue rose 11% constant currency to $1.08 billion, while adjusted operating income fell 9% from the prior year, compressing adjusted operating margin to 13.8%. The margin pressure came from a 41% drop in event-driven revenue and a mix shift toward lower-margin distribution revenue, even as total revenue grew 5% to $1.67 billion. Management reaffirmed full-year guidance for 6%-8% recurring growth, roughly 21% adjusted operating margin, 8%-12% adjusted EPS growth, and 100%+ free-cash-flow conversion, signaling confidence in second-half recovery. Closed sales rose 10% to $35.6 million and retention held at 98%, while tokenization revenue remained immaterial at $1.4 million and AI initiatives were visible mainly in a $15 million restructuring charge. The stock trades around $185, or about 20.3x P/E, leaving little room for execution slippage as investors await margin recovery in subsequent quarters.

Implication

The quarter validated the strength of Broadridge's recurring franchise with 11% constant-currency growth and 98% retention, but the 13.8% adjusted operating margin starkly exposed the near-term drag from weak event-driven activity and a low-margin revenue mix. Management's decision to maintain full-year guidance sets a high execution bar: margin must rebound toward the 21% target over the next three quarters, requiring either a recovery in event-driven revenue or meaningful productivity gains from AI and restructuring. The current price of ~$184.70 (20.3x P/E) already discounts the base case, as outlined in our WAIT rating, so we see no margin of safety unless shares pull back toward our $170 attractive entry level. Investors should watch for early warning signs: any further margin deterioration in Q2, closed sales falling below the $290-$330 million pace, or free-cash-flow conversion dipping below 100% would weaken the thesis and warrant reducing exposure. Conversely, if Q2 and Q3 show stable margins and AI/tokenization produce measurable revenue or productivity, Broadridge could justify a higher multiple and move toward our $215 bull case.

Thesis delta

Our thesis from the DeepValue report remains unchanged: Broadridge is a high-quality compounder with a strong recurring moat, but the stock is fairly valued at current levels given the margin risk. The Q1 results highlighted in the news article reinforce the critical divergence between revenue growth and profitability, which we had already identified as the key swing factor. Therefore, we maintain our WAIT rating with an attractive entry near $170 and a reassessment window of 3-6 months focused on margin recovery and execution.